Results 1 to 10 of about 12,986,553 (373)

A meta-analysis of high-dose versus low-dose 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitor-associated intracerebral hemorrhage [PDF]

, 2023
Craig I Coleman, A Karadenes, C Cassano, William L. Baker   +3 more
openalex   +1 more source

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis

Hematology Reports, 2015
Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifying the presence of Anti-factor Xa ...
M. Wei, S. Ward
semanticscholar   +1 more source

Three cases of neutralization of factor Xa inhibitors with andexanet alfa under rotational thromboelastography monitoring

Acute Medicine & Surgery
Background Factor Xa inhibitors are direct oral anticoagulants that are extremely useful in clinical applications, safe, and do not require dose adjustment.
Takeshi Yagi, Reina Kawano, Takuto Tomokage, Ryo Ayata, Yasutaka Koga, Kotaro Kaneda, Motoki Fujita, Nanami Yamanaka, Naomasa Mori, Ryosuke Tsuruta   +9 more
doaj   +1 more source

Exploring the Effects of Factor Xa Inhibitors on Thrombin Generation in People with Haemophilia

, 2023
Caroline Dix, James D. McFadyen, Huyen Tran   +2 more
openalex   +1 more source

News at XI: Moving Beyond Factor Xa Inhibitors.

Journal of Thrombosis and Haemostasis, 2023
J. Fredenburgh, J. Weitz
semanticscholar   +1 more source

Evaluating the impact of continuous venovenous hemodiafiltration on the efficacy of prophylactic fondaparinux doses: a prospective single-center observational study

Scientific Reports
Critically ill patients often need continuous renal replacement therapy (CRRT). This process can remove particles as large as 10 kDa, including medications such as fondaparinux.
Aleksander Aszkiełowicz, Karol P. Steckiewicz, Radosław Owczuk   +2 more
doaj   +1 more source

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation

Journal of Arrhythmia, 2016
Background: Although patients taking non-vitamin K antagonist oral anticoagulants (NOACs) do not require routine coagulation monitoring, high-risk patients require monitoring to assess pharmacodynamics.
Kozue Ikeda, MD, Hideaki Tachibana, MD
doaj   +1 more source

The new factor Xa inhibitor: Apixaban

Journal of Pharmacology and Pharmacotherapeutics, 2014
Cardiovascular diseases are still the most important cause of morbidity and mortality worldwide and anti-thrombotic treatment is widely used as a result. The currently used drugs include heparin and its derivatives, vitamin K antagonists, though efficacious, have their own set of limitations like unpredictable pharmacokinetic profile, parenteral route (
Bhanwra, Sangeeta, Ahluwalia, Kaza
openaire   +3 more sources

Application of Molecular Modeling to Development of New Factor Xa Inhibitors

BioMed Research International, 2015
In consequence of the key role of factor Xa in the clotting cascade and absence of its activity in the processes that do not affect coagulation, this protein is an attractive target for development of new blood coagulation inhibitors.
V. Sulimov, I. Gribkova, M. Kochugaeva, E. V. Katkova, A. Sulimov, D. Kutov, K. Shikhaliev, S. Medvedeva, Michael Krysin, E. Sinauridze, F. Ataullakhanov   +10 more
semanticscholar   +1 more source

Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality

Research and Practice in Thrombosis and Haemostasis
Background: Evaluations of andexanet alfa for the reversal of factor Xa inhibitor-associated bleeding have been small, with cohorts drawn from single/limited sites.
Huiqiao Fan, Youssef Bessada, Craig I. Coleman   +2 more
doaj   +1 more source